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Use of Recombinant Factor VIIa for Hip Surgery
in a Patient with Factor-VII Deficiency
A Case Report
By Priya K. Gopalan, MD, PhD, John C. Clohisy, MD, Amanda F. Cashen, MD, and Charles S. Eby, MD
Investigation performed at Washington University School of Medicine, St. Louis, Missouri

F

actor-VII deficiency is a rare autosomal recessive disorder affecting approximately one in 500,000 persons1.
The risk of bleeding complications depends on the factor-VII level, and patients with factor-VII activities of <1%
are at risk for spontaneous epistaxis, menorrhagia, bleeding
in the oral cavity, hemarthroses, and postoperative bleeding;
patients with activities ranging from 1% to 5% are moderately affected; and those with activities of >5% are mildly
affected2. As a result of its short half-life of six hours, factorVII-replacement strategies require frequent infusions of factor preparations. Historically, options for treatment of or
prophylaxis against bleeding in factor-VII-deficient patients
included use of fresh-frozen plasma and plasma-derived concentrates of vitamin K-dependent coagulation factors (prothrombin complex concentrates). Potential complications
associated with these products include infection with bloodborne pathogens as well as volume overload with fresh-frozen
plasma and thrombotic events with prothrombin complex
concentrates.
Recombinant activated factor VII (recombinant factor
VIIa) (NovoSeven; Novo Nordisk, Bagsvaerd, Denmark) was
approved by the United States Food and Drug Administration (FDA) in 1999 for treatment of bleeding in patients with
hemophilia A or B who have inhibitors to factors VIII and
IX, respectively. On the basis of limited clinical experience,
recombinant factor VIIa appears to also have beneficial
hemostatic effects in bleeding situations complicated by coagulopathies due to liver disease, massive hemorrhage, qualitative and quantitative platelet disorders, oral anticoagulation,
and congenital factor-VII deficiency3,4. We present a case of
off-label use of recombinant factor VIIa to prevent perioperative bleeding complications in association with a major hip
procedure in a patient with congenital factor-VII deficiency.
The patient’s wife granted permission for us to submit data
concerning the case for publication, as the patient had died
of chronic cardiac disease.

Case Report
n 2003, a seventy-six-year-old man had major bleeding after a primary right total hip replacement that had been
done without any form of factor-VII support. The surgery was
complicated by a hematoma requiring evacuation and prolonged antibiotic treatment for a wound infection. Additional
medical problems included chronic obstructive pulmonary
disease, coronary artery disease, hypertension, chronic anemia, and atrial fibrillation.
Eight days prior to transfer to Barnes-Jewish Hospital,
the patient was admitted to the referring hospital with hip
pain, changes in mental status, and fever. Enterococcus faecalis
grew on culture of fluid obtained by arthrocentesis of the right
hip, confirming a deep hip infection. Following clinical improvement with antibiotic therapy, correction of the patient’s
inherited coagulopathy was attempted. Baseline coagulation
tests showed factor-VII activity of 4% (normal range, 60% to
160%), a prothrombin time of 27.2 sec (normal range, 10 to
13 sec), and an international normalized ratio of 4.1 (normal
range, 0.9 to 1.2). Following the administration of 10 mg of
subcutaneous vitamin K and 8 U of fresh-frozen plasma over a
twenty-four-hour period, the international normalized ratio
only partially corrected from 3.9 to 2.0, necessitating transfer
to our tertiary hospital.
On admission, coagulation testing confirmed the diagnosis of inherited factor-VII deficiency, and hematology
consultants recommended perioperative correction of the
factor-VII deficiency with recombinant factor VIIa to reduce the risk of bleeding complications.
As a result of the patient’s multiple medical problems,
factor-VII deficiency, and Enterococcus infection, we recommended resection arthroplasty without reimplantation as definitive treatment. Immediately before the surgery, the patient
received 3.6 mg (38 µg/kg) of recombinant factor VIIa (Fig. 1).
Intraoperatively, gross infection was evident. The cementless
acetabular component was loose and was removed without
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Fig. 1

Doses of recombinant factor VIIa (rFVIIa) and laboratory test results in the perioperative period. The international normalized
ratio (INR), prothrombin time (PT), partial thromboplastin time (PTT), and hemoglobin level (hgb) are displayed on the vertical
axis. The time in days is displayed on the horizontal axis. The shaded column during day 1 indicates the time in the operating room. Transfusions are indicated by an up arrow for 1 U of fresh-frozen plasma and a down arrow for 1 U of red cells.

difficulty. The cementless femoral component was well fixed
and required an extended trochanteric osteotomy for explantation. The osteotomy site was fixed with cerclage wires, and
an antibiotic spacer was not placed since this was the definitive
procedure. The estimated blood loss was 700 mL. A second
3.6-mg dose of recombinant factor VIIa was administered toward the end of the procedure. Postoperatively, intermittent
pneumatic compression devices were used for prophylaxis
against deep vein thrombosis.
A postoperative infusion of 3.6 mg of recombinant factor VIIa was given approximately every five hours for the first
twenty-four hours (Fig. 1). On the second postoperative day,
the dose of recombinant factor VIIa was reduced to 2.4 mg (25
µg/kg) every six hours and was alternated with 1 U of freshfrozen plasma every six hours to conserve NovoSeven until the
blood bank was resupplied. During the third and fourth postoperative days, wound drainage averaged 200 mL/day of serosanguineous fluid. There was no evidence of bleeding or
hematoma formation. Two units of red blood cells were transfused to treat a hemoglobin level of 95 g/L, administration of
the fresh-frozen plasma was stopped, and use of recombinant
factor VIIa was continued at a dose of 2.4 mg every six hours
(Fig. 1). On the sixth day, the incision remained dry, the drain
was removed, and the dose of recombinant factor VIIa was reduced to 1.2 mg every six hours. On the eighth postoperative
day, surveillance Doppler studies of the lower extremity were

negative for deep vein thrombosis. The patient was transferred
to a skilled nursing facility for additional rehabilitation on the
ninth postoperative day.
Findings at the outpatient follow-up visit seven months
postoperatively showed no evidence of active infection. The
patient primarily used a wheelchair and was able to transfer
from bed to chair.
Discussion
ecombinant factor VIIa has been used successfully to prevent or stop bleeding in patients with a variety of inherited and acquired hemostasis disorders including congenital
factor-VII deficiency5,6. Published case reports describe the use
of recombinant factor VIIa during orthopaedic operations in
hemophiliacs with inhibitors7,8, in a patient with cirrhosis and
thrombocytopenia9 and factor VII-deficient patients undergoing synovectomy6,10, and in patients treated with primary total
hip arthroplasty11.
In this report, we described the use of recombinant factor VIIa during explantation of a hip prosthesis associated
with infection. The patient was at high risk for perioperative
bleeding complications as a result of moderate factor-VII deficiency, hypervascularity associated with the infected hip, and
the magnitude of the surgery required for explantation of a cementless femoral stem.
Anecdotal experience indicates that, during invasive
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procedures in factor-VII-deficient patients, adequate hemostasis is achieved with lower doses of recombinant factor VIIa
infused at longer intervals than is recommended for hemophiliacs with inhibitors6,12. We are aware of one report of a successful primary hip replacement performed with 29 µg/kg of
recombinant factor VIIa given every eight hours11.
In July 2005, the FDA extended the indications for use of
NovoSeven to include treatment and prevention of bleeding
complications in patients with congenital factor-VII deficiency.
Dosing guidelines are 15 to 30 µg/kg every four to six hours until hemostasis is achieved. A dose of 30 µg/kg was recommended
for our patient, who weighed 95 kg. Since recombinant factor
VIIa (NovoSeven) is supplied in 1.2, 2.4, and 4.8-mg lyophilized
vials, he initially received 3.6 mg (38 µg/kg).
Thrombotic complications associated with the use of recombinant factor VIIa in hemophiliacs are uncommon13.
However, in a recent study of patients with acute intracerebral
hemorrhage and no congenital or acquired coagulopathies,
those who received recombinant factor VIIa had significantly
more arterial thromboembolic complications than did controls (p = 0.01)14. These adverse events led to recent revisions of
the NovoSeven package-insert warnings and adverse-reaction
labeling.
Currently, recombinant-factor-VIIa dosage is not based
on laboratory monitoring. During our patient’s postoperative
period, the prothrombin time and international normalized
ratio were within the normal reference ranges except for one
time on the sixth day (Fig. 1). However, dosing decisions were
based on clinical evaluation of bleeding rather than on normalization of the international normalized ratio.
NovoSeven is an expensive recombinant protein with a
2005 wholesale price (in United States dollars) of $1540/mg
or $5852 for a 3.6-mg dose. However, the financial conse-
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quences of inadequate control of surgical bleeding in patients with inherited factor-VII deficiency are also costly as
demonstrated by this patient’s unsuccessful primary total
hip replacement.
On the basis of the successful outcome described in this
case and the recommendations of Goodnough et al.15, we suggest consideration of the following approach for patients with
moderate or severe factor-VII deficiency who are undergoing
a major orthopaedic procedure: (1) initial treatment with approximately 30 µg/kg of recombinant factor VIIa every six
hours for twenty-four hours, (2) subsequent tapering of the
dose of recombinant factor VIIa and substitution of the factor
VIIa with fresh-frozen plasma on the basis of the clinical assessment of bleeding, and the use of mechanical prophylaxis
against deep venous thrombosis. We do not believe that normalization of the prothrombin time or the international normalized ratio should be the primary end point of treatment. 
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